Article
Impact of PGL-I seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study
Registro en:
DÜPPRE, Nádia C. et al. Impact of PGL-I Seropositivity on the Protective Effect of BCG Vaccination among Leprosy Contacts: A Cohort Study. PLoS Negl Trop Dis., v.6, n.6, e1711, 8p, June 2012.
1935-2727
10.1371/journal.pntd.0001711
1935-2735
Autor
Düppre, Nádia C.
Camacho, Luiz Antonio B.
Sales, Anna M.
Illarramendi Rojas, Ximena
Nery, José Augusto C.
Sampaio, Elizabeth P.
Sarno, Euzenir N.
Bührer-Sékula, Samira
Resumen
Although leprosy has become a neglected disease, it is an
important cause of disability, and 250,000 new cases are
still diagnosed worldwide every year. The current study
was carried out in Brazil, where almost 40,000 new cases of
leprosy are diagnosed every year. The study targeted
contacts of leprosy patients, who are at the highest risk of
contracting the disease. We studied 2,135 contacts who
were diagnosed at the Leprosy Outpatient Clinic at the
Oswaldo Cruz Foundation in Rio de Janeiro, RJ, Brazil,
between 1987 and 2007. The presence of antibodies
against a specific Mycobacterium leprae antigen (PGL-I) at
the first examination and BCG vaccination status were
evaluated. PGL-I-positive contacts had a higher risk of
developing leprosy than PGL-I-negative contacts. Among
the former, vaccinated contacts were at higher risk than
unvaccinated contacts. Our results indicate that contact
examination combined with PGL-I testing and BCG
vaccination appears to justify the targeting of PGL-Ipositive
individuals for enhanced surveillance. Furthermore,
it is highly recommended that PGL-I-positive
contacts and contacts with a high familial bacterial index
(i.e., the sum of results from index and co-prevalent cases),
regardless of serological response, should be monitored.
This group could be considered as a target for chemoprophylaxis.